Literature DB >> 10660154

Analysis of effector CD4 (OX-40+) and CD8 (CD45RA+CD27-) T lymphocytes in active multiple sclerosis.

R Q Hintzen1, K Pot, D Paty, J Oger.   

Abstract

OBJECTIVE: Recently, effector T-cell subpopulations have been identified that can be distinguished by expression of members of the TNF-R family: CD4+OX-40+ cells are CD4 helper-effector cells CD8+CD45RA+CD27 cells are CD8-killer-effector cells. We investigated whether these lymphocyte subsets were increased in the active phase of multiple sclerosis (MS).
MATERIAL AND METHODS: Multiple colour immunofluorescence staining was performed on peripheral blood lymphocytes of 28 patients with active MS and of 29 healthy controls, followed by FACS analysis.
RESULTS: Frequencies of CD8-killer-effector cells showed a wide interindividual range in both groups and percentages of CD4 helper-effector cells were low. No significant difference between the groups was observed for these subsets, but CD8+CD45RA-CD27 were increased in MS. In healthy individuals, CD4 helper-effector cells correlated with the total percentages of memory cells. Moreover, CD4+ and CD8 memory cells were strongly correlated.
CONCLUSION: The here described recently identified effector CD4 and CD8 lymphocyte subpopulations were not increased in clinically active MS. It is however still possible that in MS, myelin-specific encephalitogenic cells reside within these subsets.

Entities:  

Mesh:

Year:  2000        PMID: 10660154     DOI: 10.1034/j.1600-0404.2000.00011.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Cytometric profiling in various clinical forms of multiple sclerosis with respect to CD21+, CD32+, and CD35+ B and T cells.

Authors:  Ali Zandieh; Maryam Izad; Mohammad Fakhri; Hamed Amirifard; Zahra Khazaeipour; Mohammad Hosein Harirchian
Journal:  Transl Neurodegener       Date:  2013-07-02       Impact factor: 8.014

Review 2.  Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.

Authors:  Yu Fu; Qing Lin; Zhirong Zhang; Ling Zhang
Journal:  Acta Pharm Sin B       Date:  2019-09-03       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.